At the moment, RevMed remains keenly focused on its mission to bring daraxonrasib to the masses and continue developing new medicines that target RAS. (Darren Incorvaia) This year’s meeting of the ...
An investigational oral drug that targets RAS, the dominant oncogenic driver in pancreatic cancer, nearly doubled overall survival compared with common second-line chemotherapy regimens in patients ...
From the laptops on your desk to satellites in space and AI that seems to be everywhere, I cover many topics at PCMag. I've covered PCs and technology products for over 15 years at PCMag and other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results